Cash-poor Agenus finds itself a generous partner in Gilead, shares surge
Cancer drug developer Agenus had a tough 2017 — it had to amend its antibody deal with Incyte $INCY for a quick cash infusion to overcome …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
